Harvard Bioscience Q2 FY26 net loss widens to $2.9 million; revenue rises 11% to $22.7 million - HBIO News | RalliesHarvard Bioscience Q2 FY26 net loss widens to $2.9 million; revenue rises 11% to $22.7 million
H
HBIO• Outlook
- Q3 revenue forecast set at USD 21 million–USD 22.6 million; adjusted EBITDA seen at USD 1.5 million–USD 2.5 million.
- Raised full-year revenue outlook to 3%–5% growth; adjusted gross margin target set at 57%–59%.
Q2 results and operating trends
- Harvard Bioscience Q2 revenue rose 11% to USD 22.7 million; GAAP net loss widened to USD 2.9 million.
- Adjusted EBITDA increased to USD 1.7 million; gross margin slipped 0.8 percentage points to 55.6%.
- Management cited stronger demand, solid traction in telemetry and cellular and molecular technology products, with mix pressure from CMT and China.
